Denosumab may help prevent Revision Procedures Following Hip Replacement: Study

Data analysis revealed the following facts.

• Between Dec 12, 2012, and June 24, 2018, 51 patients were assessed for eligibility, of whom 24 were randomly assigned to study treatment.
• Two patients had their revision surgery cancelled for unrelated reasons, leaving 22 patients (ten in the denosumab group) for analysis of the primary outcome.
• There were 83% fewer osteoclasts at the osteolysis membrane–bone interface in the denosumab versus the placebo group (median 0·05 per mm [IQR 0·11] vs 0·30 mm [0·40], p=0·011).
• No deaths or treatment-related serious adverse events occurred. Seven adverse events, including one severe adverse event, occurred in four (36%) of 11 patients in the denosumab group.
• In the placebo group ten adverse events, including three severe adverse events, occurred in five (38%) of 13 patients.

"This is the first clinical trial of an investigational drug for osteolysis that shows tissue-specific biological efficacy. These results justify the need for future trials that target earlier-stage disease to test for clinical efficacy in reducing the need for revision surgery."wrote the team.

For the full article follow the link: https://doi.org/10.1016/S2665-9913(20)30394-5

Primary source: Rheumatology